New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy Co-mutations, viral link, potential common susceptibility emerge from two studies Jun 12, 2024
Telomerase Inhibitor Approved for MDS-Related Anemia Imetelstat indicated for lower-risk myelodysplastic syndromes with transfusion-dependent anemia Jun 07, 2024
'Unusual' Cancers After Pandemic; A Win in TNBC; Shortage Pauses Clinical Trial News, features, and commentary about cancer-related issues Jun 06, 2024
Star Singer's Illness; AI Imitating the Dead; Internet-Addicted Brains Health news and commentary gathered by ·¬ΗΡΙηΗψapp staff Jun 05, 2024
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML The benefit-risk profile could change the treatment paradigm in CML, expert says May 31, 2024
Ignoring Colonoscopy Advice; Inflamed Tongue, Then Cancer; Acupuncture for Dry Mouth News, features, and commentary about cancer-related issues May 24, 2024
Ending Oncology's Toxic Relationship With High Chemotherapy Doses Optimizing doses can improve patient outcomes and lower costs May 10, 2024
Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show Study finds survival is comparable to that seen in younger patients in VIALE-A trial May 09, 2024
Fresh and Frozen Embryo Transfers May Increase Risk of Childhood Leukemia However, overall cancer risk was not higher after fertility treatments vs natural conception May 02, 2024
High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL Undetectable disease rate over 90%, ctDNA also promising for earlier detection of recurrence Apr 24, 2024
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers "All-in-one" approach appears safe, effective, in patients with relapsed/refractory disease Apr 24, 2024
Immunotherapy During Pregnancy Just as Safe as Other Cancer Drugs However, use should be avoided "if possible" due to risk of rare immune-related adverse events Apr 17, 2024
1,000 Paper Cranes Can Bring Our Patients One Step Closer to Healing We must remind our patients to hold on to hope Apr 11, 2024
Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendations News, features, and commentary about cancer-related issues Mar 29, 2024
Breastfeeding Tied to Reduced Childhood Leukemia Risk Lower pediatric ALL risk in Danish study when mothers exclusively breastfed for 3 months or more Mar 27, 2024
FDA Approves New Frontline Regimen for Aggressive ALL Ponatinib lands indication in combination with chemo for Philadelphia chromosome-positive cases Mar 22, 2024
Broader Cancer Risk With CAR-T? AI for Physician Burnout; 'Lollipops' ID Oral Cancer News, features, and commentary about cancer-related issues Mar 22, 2024
EPA Imposes New Limit on Medical Sterilization Chemical, Citing Cancer Risk Rule would lower emission standards for ethylene oxide by 90%, agency says Mar 15, 2024
FDA Approves First CAR-T for Chronic Lymphocytic Leukemia Lisocabtagene maraleucel (Breyanzi) nabs new indication for relapsed or refractory CLL/SLL Mar 15, 2024
FDA Panel Endorses Imetelstat for MDS-Related Anemia By 12-2 vote, members find improvement in transfusion independence outweighs risk Mar 14, 2024
Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues 'Charity' News, features, and commentary about cancer-related issues Mar 14, 2024
FDA Staff Cast Doubt on Novel Drug for MDS-Related Anemia Agency asking its advisors if benefits outweigh risks for patients who fail on standard treatment Mar 12, 2024
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu News, features, and commentary about cancer-related issues Mar 07, 2024
All-Oral AML Regimen Shows Promise for Older, Unfit Patients Response rate of 64% in newly diagnosed patients, 46% in those with refractory/relapsed disease Mar 05, 2024
Toxic Gas That Sterilizes Medical Devices Prompts Safety Rule Update The EPA is set to take action after public outcry Mar 03, 2024
New Drugs Yield Limited Benefit; Big Jump in Drug Prices; AI Boost for Mammo Results News, features, and commentary about cancer-related issues Mar 01, 2024
Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML But it's unlikely stem cell transplants will ever be large-scale cure for HIV, says expert Feb 14, 2024
FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia Complete response rate of 86%, median event-free survival approaching 4 years with crenolanib Feb 13, 2024
No Relief From Drug Shortages; New Lymphedema Guideline; A 'Good' Patient No More News, features, and commentary about cancer-related issues Feb 09, 2024
All-Oral Therapy Promising in Higher-Risk MDS, CMML In small trial, overall response rate was 95% Feb 05, 2024
Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Says Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer News, features, and commentary about cancer-related issues Jan 19, 2024
Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors While safe, the results do not support use of the drug in anthracycline-exposed survivors Jan 10, 2024
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
Completely Oral Regimen Effective, Feasible in APL 97% of patients alive and relapse-free at 3 years Dec 10, 2023
